GlassScriptPhysician profile
David K Close
NPI 1558335844
$13,102.41
in general payments reported to CMS, 2019-2025
52 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,858 · 2020: $1,360 · 2021: $2,328 · 2022: $1,792 · 2023: $1,479 · 2024: $1,934 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,763.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,890.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,622.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,197.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $748.61 | 2019-2025 | |
| Amarin Pharma, INC. | $635.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $607.47 | 2019-2022 | |
| Amgen INC. | $516.73 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.87 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $462.76 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $421.28 | 2019-2022 | |
| Abbott Laboratories | $403.62 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $266.89 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $265.08 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $231.83 | 2019-2025 | General - Erectile Dysfunction, Bodyguardian, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $217.15 | 2019-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Close listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.